One measure of a treatment's effectiveness is the regularity with which it proves superior to placebo. That measure also tells us about the consequences of using a treatment as a standard against which to test a new agent. To assess the frequency with which approved and presumably effective antidepressants and anxiolytics show statistical superiority over placebo, we reviewed placebo-controlled clinical trials of antidepressants and anxiolytics in a singularly large database free of publication bias. We evaluated clinical-trial data from the nine antidepressants approved by the FDA between 1985 and 2000. These trials comprised 10 030 depressed patients who participated in 52 antidepressant clinical trials evaluating 93 treatment arms of a new or established antidepressant. Similarly, we examined clinical trials data from the 13 anxiolytics approved by the FDA between 1985 and 2000. These trials comprised 8340 anxious patients, 40 anxiolytic clinical trials and 75 treatment arms of a new or established anxiolytic. Fewer than half (48 %, 45\93) of the antidepressant treatment arms showed superiority to placebo. Among anxiolytics, 48 % (36\75) of anxiolytic treatment arms showed superiority over placebo. These data suggest that conventional psychopharmacologic treatments for depression and anxiety are superior to placebo less than half the time and call into serious question the widely propagated notion that placebo controls can be dispensed with in clinical trials of these agents. Exclusion of placebo controls in favour of non-inferiority trials would result in a high likelihood that ineffective antidepressants and anxiolytics would be foisted on the public and, less dangerous but also problematic, that potentially effective agents would be missed.
Introduction
Restrictions on placebo use in medical research, including psychopharmacology research, are being considered in several quarters. For example, according to the revised version of the Declaration of Helsinki (2000) : ' The benefits, risks, burdens and effectiveness of a new method should be tested against those of the best current prophylactic, diagnostic, and therapeutic methods. ' For now, the USA's Food and Drug Administration (FDA) continues to require two or more positive placebocontrolled trials to approve a new agent. But the European Agency for the Evaluation of Medicinal Products (EMEA, 2001 ) has incorporated and implemented a broad interpretation of the revised Declaration of Helsinki and many IRBs (or ethics committees) in the USA and Europe are reluctant to allow placebo controls in anxiolytic and antidepressant trials or simply disallow placebo in all such trials.
Recent articles, editorials, and letters have articulated the ethical and scientific issues pertinent to the use of placebo controls (Emanuel and Miller, 2001 ; Lavori, 2000 ; Leber, 2000 ; Miller, 2000) . Among the controversies of particular importance to the conduct of antidepressant and anxiolytic clinical trials is whether the new agent should be compared to placebo or ' standard ' treatment (non-inferiority trial). As is often the case in such matters, the debate is fuelled less by information than by misconceptions, intuition, and the posturing of stakeholders. One piece of information central to this debate, and as yet missing, is the regularity with which the available ' standard ' antidepressants and anxiolytics prove superior to placebo. This paper offers such information.
Methods
We reviewed the Summary Basis of Approval (SBA) data from the FDA archives, under the Freedom of Information Act (US Congress, 1996) , that describes clinical trial outcomes for recently approved antidepressants (n l 9) and anxiolytics (n l 13). These data were obtained by a specific request to the FDA (Freedom of Information Staff, Room 12A-16, 5600 Fishers Lane, Rockville, MD 20857). The data include ' pivotal ' clinical trial data that were used for assessing the effectiveness of new agents approved from 1985 to 2000. Under Title 21 of the Code of Federal Regulations (FDA, 1997), these pivotal studies by convention and practice are randomized, double-blind, and placebo controlled, with established criteria for the sample under study and defined criteria for response. Typically, these are phase 2 and 3 studies with several hundred patients. Studies are designated as pivotal without regard to outcome as many do not demonstrate statistical superiority of the antidepressant or anxiolytic over placebo.
We have previously described methods of data collection, details of trial designs as well as methods of analysis. Factors such as number of patients, duration of trial, specific diagnostic instruments used are described and available in FDA SBA reports and have been published earlier for the antidepressant trials (Khan et al., 2000 (Khan et al., , 2001 .
Among the 52 antidepressant clinical trials conducted during the development of the 9 antidepressants, there were 79 new (test) treatment arms for the antidepressant under investigation as several trials evaluated multiple doses of the new antidepressant ; of these, 10 treatment arms evaluated doses of antidepressant that are not approved for marketing. An additional 24 treatment arms evaluated an established antidepressant (active comparator) for a total of 93 antidepressant treatment arms (Table 1) .
Among the 40 anxiolytic clinical trials, there were 62 new (test) treatment arms for the anxiolytic under investigation ; of these, 1 panic disorder treatment arm evaluated a dose that is not approved for marketing. An additional 14 treatment arms evaluated an established anxiolytic (active comparator) for a total of 75 anxiolytic treatment arms (Table 2) .
We examined the results from each of the new and established treatment arms for frequency of statistical superiority over placebo (p 0n05) (Tables 1 and 2). Table 1 describes the 3462 depressed patients assigned to placebo in 52 clinical trials compared to the 4967 patients assigned to a new antidepressant evaluating a dose that is currently approved for market and the 1601 patients assigned to an established antidepressant. Forty-five of the 93 (48n4 %) trials of new and established anti- depressants showed statistical superiority over placebo. There were an additional 10 antidepressant treatment arms that evaluated doses deemed inadequate or below therapeutic dose by the FDA. None of them showed statistical significance over placebo. Table 2 describes the 2428 patients with five types of anxiety disorders assigned to placebo in 40 clinical trials, compared to the 5062 patients assigned to a new anxiolytic evaluating a dose that is currently approved for market and the 850 patients assigned to established anxiolytics. Thirty-six of the 75 (48n0 %) trials of new and established anxiolytics showed statistical superiority over placebo.
Results

Discussion
Currently available antidepressants and anxiolytics do not regularly show statistical superiority to placebo. In fact, in more than half of the trials (87\168, 51n8 %), response to antidepressants and anxiolytics was indistinguishable from response to placebo. Based on these data, if new antidepressants and anxiolytics were tested against ' standard ' treatment rather than placebo, about half of the trials would yield invalid results : ineffective treatments mistakenly accepted as effective and effective treatments mistakenly designated inactive.
To our knowledge, ours is the first report assessing how often antidepressants and anxiolytics are superior to placebo in clinical trials. However, our findings are similar to earlier publications assessing the magnitude of difference between drug and placebo in antidepressant trials (Khan et al., 2000 (Khan et al., , 2001 Kirsch and Sapirstein, 1998 ; Storosum et al., 2001) .
These data, in combination with other recent reports showing increasing magnitude of placebo response (Walsh et al., 2002) and two failed trials (Hypericum Depression Trial Study Group, 2002 ; Shelton et al., 2001) with St John's Wort, bolster the idea of using placebo. For example, exclusion of placebo by the Hypericum Depression Trial Study Group could easily have led to the incorrect conclusion that sertraline and St John's Wort are equivalent treatments for major depressive disorder.
It is worth noting that the less than impressive showing of antidepressants and anxiolytics in these clinical trials data does not necessarily reflect the effectiveness of these agents in clinical practice. The depressed and anxious patients participating in clinical trials are a unique segment of the population with these conditions. They are mild to moderately ill, not suicidal, and without significant psychiatric or medical co-morbidity. The clinical features and the clinical trials process itself, which includes considerable evaluation and attention and creates high expectations for improvement, renders clinical trials participants particularly likely to improve with placebo. Data from several sources, for example, suggest that drug placebo differences are robust in the chronic and severely ill depressed patients who are not usually the subjects of clinical trials.
Other disorders such as obsessive-compulsive disorder and schizophrenia may have a lower placebo response than depression or anxiety disorders allowing for larger drug vs. placebo differences.
The FDA SBA reports consist of a large database, include all data from all clinical trials and are free of publication bias. In this way they are ideally suited for answering questions, such as the one we posed, requiring a large number of trials. But these data have some limitations. For example, they do not allow us to calculate the proportion of patients who experienced a clinically meaningful response, compare results across trials or calculate effect sizes.
In addition, we note that the data are a continued analysis of earlier published reports and are not from a new source (Khan et al., 2000) . Also, the variability in individual study inclusion\exclusion criteria, not discernible via SBA reports, may have contributed to these findings.
In conclusion, the risks of placebo treatment do warrant the serious consideration they have received. The elimination of placebo controls calls for serious consideration as well. It is in the public interest for both matters to be informed not only by broad ethical and scientific principles but also by the available data.
